The era of lipidomics begins with the improvement of analytical techniques over the last twenty years, especially the mass spectrometry-based strategies. Lipids have multiple roles in inflammation and organ damage, protective and harmful, whether structural lipids of the cell membrane or lipid signaling molecules. A lipid profile is a specific marker of damage to individual organs, and lipid signals are transmitted within or between cells (e.g., PPARs and exosomes). Molecules that enable the transport of lipids across the cell and mitochondrial membranes, their metabolism, and redirection of lipid metabolites into peroxisomes play a central role in various types of IR injury (e.g., carnitine, ceramide, or cardiolipin). In particular, drug targets may be enzymes involved in the transmembrane transport of lipids (e.g., CD36, SRB1, and flipases). Drugs that induce a metabolic shift from free fatty acids' ß-oxidation to aerobic glycolysis (e.g., meldonium and trimetazidine) may reduce the damage caused by lipototoxicity.
The role of lipids as a biomarker of IR injury has been partially elucidated. Clinical studies have shown the importance of ceramide, phosphatidylcholine, and lysophosphatidylcholine as risk factors for CVD independent of total HDL cholesterol. Less is known about lipid signals transmitted by extracellular vesicles. On the other hand, the development of drugs that would target specific steps in lipid turnover and lipotoxicity remains to be investigated. Also, lipids are essential components of the cell's energetics, which is especially important in testing drugs that act in some models of IR injury, such as sepsis. A challenging issue is to prevent the accumulation of lipids that leads to lipototoxicity and induce metabolic changes that will protect cells from cell death and, at the same time, not impair complete recovery after injury. Also, it remains to be found how drugs that affect the lipid profile act in simultaneous damage to multiple organs.
The thematic issue should focus on the following topics:
• the role of lipids in the development of IR injury;
• analytical possibilities of lipidomics in IR injury research;
• finding new targets for the effect of drugs on lipid environment in IR injury and repurposing for known drugs
• beneficial and harmful effects of drugs on lipids in IR damage
• development of new experimental models focusing on lipidomics and IR, alternative models (C. ellegans et al.)
• effect of drugs on the organ cross-talk in IR injury
• clinical trials of drugs that affect lipid metabolism in IR damage
All submissions need to follow the guidelines of the respective sections.
The era of lipidomics begins with the improvement of analytical techniques over the last twenty years, especially the mass spectrometry-based strategies. Lipids have multiple roles in inflammation and organ damage, protective and harmful, whether structural lipids of the cell membrane or lipid signaling molecules. A lipid profile is a specific marker of damage to individual organs, and lipid signals are transmitted within or between cells (e.g., PPARs and exosomes). Molecules that enable the transport of lipids across the cell and mitochondrial membranes, their metabolism, and redirection of lipid metabolites into peroxisomes play a central role in various types of IR injury (e.g., carnitine, ceramide, or cardiolipin). In particular, drug targets may be enzymes involved in the transmembrane transport of lipids (e.g., CD36, SRB1, and flipases). Drugs that induce a metabolic shift from free fatty acids' ß-oxidation to aerobic glycolysis (e.g., meldonium and trimetazidine) may reduce the damage caused by lipototoxicity.
The role of lipids as a biomarker of IR injury has been partially elucidated. Clinical studies have shown the importance of ceramide, phosphatidylcholine, and lysophosphatidylcholine as risk factors for CVD independent of total HDL cholesterol. Less is known about lipid signals transmitted by extracellular vesicles. On the other hand, the development of drugs that would target specific steps in lipid turnover and lipotoxicity remains to be investigated. Also, lipids are essential components of the cell's energetics, which is especially important in testing drugs that act in some models of IR injury, such as sepsis. A challenging issue is to prevent the accumulation of lipids that leads to lipototoxicity and induce metabolic changes that will protect cells from cell death and, at the same time, not impair complete recovery after injury. Also, it remains to be found how drugs that affect the lipid profile act in simultaneous damage to multiple organs.
The thematic issue should focus on the following topics:
• the role of lipids in the development of IR injury;
• analytical possibilities of lipidomics in IR injury research;
• finding new targets for the effect of drugs on lipid environment in IR injury and repurposing for known drugs
• beneficial and harmful effects of drugs on lipids in IR damage
• development of new experimental models focusing on lipidomics and IR, alternative models (C. ellegans et al.)
• effect of drugs on the organ cross-talk in IR injury
• clinical trials of drugs that affect lipid metabolism in IR damage
All submissions need to follow the guidelines of the respective sections.
